Tumor Suppressor Protein p53
"Tumor Suppressor Protein p53" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Nuclear phosphoprotein encoded by the p53 gene (GENES, P53) whose normal function is to control CELL PROLIFERATION and APOPTOSIS. A mutant or absent p53 protein has been found in LEUKEMIA; OSTEOSARCOMA; LUNG CANCER; and COLORECTAL CANCER.
| Descriptor ID |
D016159
|
| MeSH Number(s) |
D12.776.157.687.650 D12.776.260.820 D12.776.624.776.775 D12.776.660.720.650 D12.776.744.845
|
| Concept/Terms |
Tumor Suppressor Protein p53- Tumor Suppressor Protein p53
- p53 Antigen
- TP53 Protein
- TRP53 Protein
- p53 Tumor Suppressor Protein
- pp53 Phosphoprotein
- Phosphoprotein, pp53
- Cellular Tumor Antigen p53
- Oncoprotein p53
|
Below are MeSH descriptors whose meaning is more general than "Tumor Suppressor Protein p53".
Below are MeSH descriptors whose meaning is more specific than "Tumor Suppressor Protein p53".
This graph shows the total number of publications written about "Tumor Suppressor Protein p53" by people in this website by year, and whether "Tumor Suppressor Protein p53" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2014 | 1 | 0 | 1 |
| 2016 | 1 | 1 | 2 |
| 2017 | 2 | 0 | 2 |
| 2018 | 0 | 1 | 1 |
| 2019 | 2 | 3 | 5 |
| 2020 | 2 | 2 | 4 |
| 2021 | 1 | 1 | 2 |
| 2022 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Tumor Suppressor Protein p53" by people in Profiles.
-
Mechanism of apoptosis activation by Curcumin rescued mutant p53Y220C in human pancreatic cancer. Biochim Biophys Acta Mol Cell Res. 2022 Dec; 1869(12):119343.
-
Structural studies of antitumor compounds that target the RING domain of MDM2. Protein Sci. 2022 Aug; 31(8):e4367.
-
Mesoscopic protein-rich clusters host the nucleation of mutant p53 amyloid fibrils. Proc Natl Acad Sci U S A. 2021 03 09; 118(10).
-
Target Genetic Abnormalities for the Treatment of Colon Cancer and Its Progression to Metastasis. Curr Drug Targets. 2021; 22(7):722-733.
-
Pan-cancer analysis reveals TAp63-regulated oncogenic lncRNAs that promote cancer progression through AKT activation. Nat Commun. 2020 10 14; 11(1):5156.
-
Targeting the p53-MDM2 pathway for neuroblastoma therapy: Rays of hope. Cancer Lett. 2021 01 01; 496:16-29.
-
Targeted Brain Tumor Therapy by Inhibiting the MDM2 Oncogene: In Vitro and In Vivo Antitumor Activity and Mechanism of Action. Cells. 2020 Jul 01; 9(7).
-
Chemopreventive Agent 3,3'-Diindolylmethane Inhibits MDM2 in Colorectal Cancer Cells. Int J Mol Sci. 2020 Jun 30; 21(13).
-
Targeting MDM2 for novel molecular therapy: Beyond oncology. Med Res Rev. 2020 05; 40(3):856-880.
-
MDM2-NFAT1 dual inhibitor, MA242: Effective against hepatocellular carcinoma, independent of p53. Cancer Lett. 2019 09 10; 459:156-167.